Q4 FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Mar 5, 2026
Contineum Therapeutics, Inc. (CTNM) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$11.1 million. As of Sep 30, 2026 it held $244.5 million in cash and investments and $6.3 million in total debt.
Revenue
$0
Net income
$-18.70M
-46.2% vs year-ago quarter
Operating cash flow
$-11.06M
+9.3% vs year-ago quarter
Free cash flow
$-11.06M
+10.0% vs year-ago quarter
EPS
$-0.49
-22.5% vs prior quarter
Dividend per share
None
Shares outstanding
23.10M
-17.6% vs prior quarter
Net cash
$238.22M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTNM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1855175
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$21.0M | -$17.4M | -$16.9M | -$17.1M | -$14.9M |
| Net income | -$18.7M | -$15.2M | -$14.5M | -$15.2M | -$12.8M |
| Diluted EPS | -$0.49 | -$0.40 | -$0.39 | — | — |
| Operating cash flow | -$11.1M | -$11.5M | -$16.3M | -$13.0M | -$12.2M |
| Free cash flow | -$11.1M | -$11.5M | -$16.6M | -$13.1M | -$12.3M |
| Total assets | $257.0M | $250.4M | $261.3M | $276.6M | $190.8M |
| Total liabilities | $11.6M | $10.7M | $11.3M | $15.7M | $10.4M |
| Stockholders' equity | $245.4M | $239.7M | $250.0M | $261.0M | $180.5M |
| Cash and investments | $244.5M | $236.6M | $246.3M | $262.9M | $182.4M |
| Total debt | $6.3M | $6.6M | $7.0M | $8.2M | $5.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 13, 2026 | Jul 13, 2026 |
All 201 Contineum Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.